Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

0
31
Trevena, Inc. announced it is advancing TRV045 into clinical development, following receipt of a notification from the US FDA that the study may proceed.
[Trevena, Inc.]
Press Release